Overall, postbiotics may represent a promising therapeutic strategy for targeting neurodegenerative processes in PD, although their safety, efficacy, optimal dosing, and clinical utility require further investigations.
A systematic evaluation of the role of postbiotics in the prevention and management of CI across different neurological and metabolic disorders is provided, and the available preclinical findings with potential therapeutic implications and future directions are summarized.
Priti Dipa, Neha, Snehashis Mandal et al.· Ageing Research Reviews· 0 citations
Combined in silico and experimental findings highlight hesperidin’s strong binding to key molecular targets, whereas experimental evidence also confirms its antioxidant, anti-inflammatory, and anti-apoptotic effects, supporting its potential as a disease-modifying candidate in PD therapy.
Seyawash Ghani, Diksha Dalal, Anish Singh et al.· Current Behavioral Neuroscie...· 0 citations
The gut microbiota acts as an upstream regulator of AD pathology through interconnected molecular mechanisms, and microbiota-targeted interventions have the potential to modulate these pathways and improve cognitive outcomes, although results vary across studies.
Javeria Fatima, Y. Siddique· CNS and Neurological Disorde...· 0 citations
This study evaluates plant‐derived bioactive peptides critically for their dualistic neuroprotective versus neuro‐destructive potential in NDs, clarifying the underlying molecular mechanisms and translational barriers.
This chapter summarizes current knowledge of the microbiota-gut-brain axis (MGBA) and elucidates how intestinal microbes and their metabolites communicate with the central nervous system via neural, immune, endocrine, and metabolic pathways.
Gopal Khodve, Shaswat Raval, Sugato Banerjee· International review of neur...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
